About Nectero Medical
Nectero Medical is a Healthcare company based in Bethlehem (United States) founded in 2019. An endovascular device for treating abdominal aortic aneurysms is developed. Nectero Medical has raised $115.5 million across 3 funding rounds from investors including Boston Scientific, Norwest Venture Partners and BioStar Capital. The company has 6 employees. Its chief executive, as recorded, is Jack Springer. Nectero Medical offers products and services including Nectero EAST System. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices. Its legal entity is NECTERO MEDICAL LLC. Its competitors include Mercator MedSystems, PharmaIN and Advanced NanoTherapies; 3 of its 3 listed competitors have raised funding.
Company details
Nectero Medical was founded in 2019 and is headquartered in Bethlehem, United States. The company operates in the medical device sector, focusing on cardiovascular treatments. An endovascular aneurysm stabilization system is developed by the firm, through which a stabilizer agent is delivered directly to the aneurysm site. This approach is intended to reduce aneurysm growth rates and enhance aortic tissue strength. Leadership is provided by CEO Jack Springer.
- Headquarters Bethlehem, United States
- Employees 6
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website necteromedical.com
- Social LinkedIn
- Legal Name Nectero Medical Llc
- Total Equity Funding$115.5M (USD)
in 3 rounds
- Latest Funding Round$96M (USD), Series D
Apr 2024
- InvestorsBoston Scientific
& 4 more
- Employee Count6
Products & Services of Nectero Medical
Nectero Medical offers a comprehensive portfolio of products and services, including Nectero EAST System.
Endovascular system to stabilize abdominal aortic aneurysms.
Funding Insights of Nectero Medical
Nectero Medical has successfully raised a total of $115.5M across 3 strategic funding rounds. The most recent funding activity was a Series D round of $96 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $115.5M
- Total Rounds 3
- Last Round Series D — $96M
- Investors Count 5
All 3 funding rounds of Nectero Medical with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2024 | $96M | Series D | – | Norwest Venture Partners | |
| Sep 2021 | $19.5M | Series C | – | Boston Scientific | – |
| Apr 2020 | Series B | – | – | – |
5 investors in total: 5 institutional.
Investors in Nectero Medical
Nectero Medical has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Boston Scientific, Norwest Venture Partners and BioStar Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital and growth equity firm providing investments and resources to entrepreneurs in various sectors. | 1961 | nvp.com | Menlo Park, United States | |
Healthtech startups are funded by BioStar Capital's venture capital efforts. | biostarcapital.com | Charlevoix, United States | ||
Healthcare venture capital investments are made by Cadence Healthcare Ventures. | cadencehcvc.com | Ross, United States | ||
Tech and life sciences focused VC firm investing in geographies such as the US | aphelioncapital.net | Mill Valley, United States | ||
Wide range of medical devices | 1979 | bostonscientific.com | Marlborough, United States |
Investor details for Nectero Medical
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Nectero Medical
1 people are tracked at Nectero Medical (1 in leadership); the tracked headcount is 6.
| Name | Role | Group |
|---|---|---|
Jack Springer | CEO | Leadership |
Complete people profiles for Nectero Medical
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Nectero Medical
3 dated milestones of Nectero Medical across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Nectero Medical is founded.
- Funding First funding round.
- Funding Latest funding round, Series D, of $96.0M.
Competitors of Nectero Medical
Nectero Medical has 3 listed competitors in our database, 3 of them funded. They include Mercator MedSystems, PharmaIN and Advanced NanoTherapies.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| mercatormed.com | 2000 | San Leandro, United States | $31.8M | Catheter-guided microfluid injection systems are developed for targeted tissue therapies. | ||
| pharmain.com | 2001 | Bothell, United States | $1.5M | Proprietary drug delivery platforms are developed for API enhancement. | ||
| advancednanotherapies.com | 2018 | Los Gatos, United States | $26.38M | Developer of a drug delivery device for cardiac vascular diseases |
Detailed competitors of Nectero Medical
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Nectero Medical
The website of Nectero Medical (necteromedical.com) receives about 1.1K visits a month.
- Monthly visits1.1K
▼ 4.9% vs previous month
Top companies in Cardiac and Vascular Disorders
3 companies that operate in the same segment as Nectero Medical (Cardiac and Vascular Disorders) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | 255 | ||
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nectero Medical
Complete news archive for Nectero Medical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nectero Medical
Nectero Medical was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Nectero Medical is headquartered in Bethlehem, United States.
Jack Springer is the CEO of Nectero Medical, as recorded in our data.
Nectero Medical is a funded company, having raised a total of $115.5M across 3 funding rounds to date.
Nectero Medical has 6 employees.
Nectero Medical was founded in 2019 and is headquartered in Bethlehem, United States. The company operates in the medical device sector, focusing on cardiovascular treatments. An endovascular aneurysm stabilization system is developed by the firm, through which a stabilizer agent is delivered directly to the aneurysm site. This approach is intended to reduce aneurysm growth rates and enhance aortic tissue strength. Leadership is provided by CEO Jack Springer.
Nectero Medical's top competitors include Mercator MedSystems, PharmaIN and Advanced NanoTherapies.
Nectero Medical offers Nectero EAST System.
Nectero Medical has 5 investors. Key investors include Boston Scientific, Norwest Venture Partners, BioStar Capital, Cadence Healthcare Ventures, and Aphelion Capital.
Nectero Medical operates through Nectero Medical Llc.